Depressed patients perception of the efficacy of electroconvulsive therapy and venlafaxine therapy
Language English Country Sweden Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
18063943
PII: NEL280607A09
Knihovny.cz E-resources
- MeSH
- Antidepressive Agents, Second-Generation therapeutic use MeSH
- Cyclohexanols therapeutic use MeSH
- Depressive Disorder psychology therapy MeSH
- Adult MeSH
- Electroconvulsive Therapy psychology MeSH
- Middle Aged MeSH
- Humans MeSH
- Psychiatric Status Rating Scales MeSH
- Retrospective Studies MeSH
- Self-Assessment MeSH
- Patient Satisfaction * MeSH
- Severity of Illness Index MeSH
- Venlafaxine Hydrochloride MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Antidepressive Agents, Second-Generation MeSH
- Cyclohexanols MeSH
- Venlafaxine Hydrochloride MeSH
BACKGROUND: The aim of our study was to evaluate the efficacy of electroconvulsive (ECT) and venlafaxine therapy from the patient's point of view. METHODS: We used a retrospective chart review from 22 inpatients who underwent ECT and 22 patients treated with venlafaxine due to resistant unipolar or bipolar depression. We used bilateral ECT in a median of 8 (IQR 7-9.7) sessions and venlafaxine therapy with a median daily dosage of 225 mg (IQR 150-225 mg) for a median of 4 (IQR 4-5) weeks. The main outcome was change in a self-evaluation scale - Short Form of the Beck Depression Inventory (BDI-SF). The response was defined as the decreasing of the BDI-SF score by >or=50%, remission as decreasing of BDI-SF score
